Research programme: migraine prophylactic therapy - Sepracor

Drug Profile

Research programme: migraine prophylactic therapy - Sepracor

Alternative Names: SEP 225382

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator Sepracor
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 15 Mar 2004 Preclinical trials in Migraine in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top